The FDA has cleared Century Therapeutics' IND application to commence a phase I study of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.
China's National Medical Products Administration (NMPA) has cleared an IND for CM-369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by Tiannuojiancheng Pharma, a joint venture between InnoCare Pharma and Keymed Biosciences.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and > 80% of cases are associated with the most common risk factor of liver cirrhosis.
Seagen has described new antibody-drug conjugates (ADCs) comprising antibodies covalently bound to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker and reported to be useful for the treatment of cancer.
WuXi Biologics (Shanghai) and WuXi Biologics Ireland have divulged antibody-drug conjugates (ADCs) comprising anti-TROP2 antibodies covalently linked to cytotoxic drugs via linker reported to be useful for the treatment of cancer.
RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer.
Mersana Therapeutics has entered into an option agreement with GSK for the codevelopment and commercialization of XMT-2056, an Immunosynthen antibody-drug conjugate (ADC) that targets a novel epitope of HER2.
A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells (iPSCs) to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors.
RSS